Lidocaine IV infusion for pancreatic cancer treatment
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase study tests whether giving lidocaine through an IV infusion can help treat pancreatic cancer. It will enroll people with confirmed pancreatic cancer that can be measured on scans, including some cases discovered to have spread during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed pancreatic cancer (adenocarcinoma) from biopsy or fluid testing
- Your cancer must be “resectable,” or it may be found to have spread during surgery
- There must be measurable tumors visible on scans (at least one meets study limits)
- You can sign informed consent after reading the study details
- You must not have major heart rhythm or conduction problems (or recent disqualifying heart treatments)
- You cannot have certain medical histories like serious blood clot disease or uncontrolled hepatitis/HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called transcatheter arterial infusion, where chemotherapy drugs are delivered directly to the tumor through a thin tube in an artery. It's for people with advanced pancreatic cancer who haven't had other treatments yet.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for pancreatic cancer that hasn't spread. It aims to see if the combination can shrink tumors and improve survival with manageable side effects.
This study tests whether a new combination of super-precise radiation (guided SBRT), standard chemotherapy, and a newer immune medicine called Ivonescimab can slow or shrink pancreatic tumors that cannot be removed by surgery. The goal is to find a more effective treatment option.
This trial tests whether focused radiation on nerves in the abdomen can reduce pain from advanced pancreatic cancer. If you join, you'll receive this treatment and your pain levels will be monitored.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.